Cansino Biologics 康希诺
4 significant filings since 31 May 2026: 4 on equity incentive. The latest, on 17 Sep 2026: 关于向2025年A股限制性股票激励计划激励对象授予部分预留限制性股票的公告. 2 unverified reports logged, the latest on 21 Aug 2026.
自 31 May 2026 起有 4 份重大公告：equity incentive 4 份。最新一份（17 Sep 2026）：关于向2025年A股限制性股票激励计划激励对象授予部分预留限制性股票的公告。记录了 2 条未经核实的报道，最新一条见于 21 Aug 2026。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳 | Unrated | 23 Nov 2025 | 2 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 2 reports. 每行为该券商近十二个月的最新研报；2 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。